Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with mantle cell lymphoma (MCL) and in patients with Waldenstrom's macroglobulinemia (WM). The Company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

ASH 2012

Pharmacyclics had 9 oral and 9 poster presentations at this year's American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib.  Among the data presented at ASH were updates on the safety and efficacy of ibrutinib in the most mature clinical programs of chronic lymphocytic leukemia (CLL) and MCL. Two of the CLL oral presentations were acknowledged as 'Best of ASH' during the event. Additionally, investigators presented data in diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM).  Most of the oral presentations can be found on the Company's website. 

Phase II/III clinical trials initiated with ibrutinib in the collaboration:

  • Phase III study of ibrutinib versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), RESONATE™. This trial is a randomized, multi-center, open-label Phase III trial of ibrutinib as a monotherapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to ofatumumab. This global study is open and Pharmacyclics plans to enroll 350 patients worldwide. The Company anticipates having this st
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/18/2014)... 17, 2014 pH measurement and control ... the pharmaceutical, chemical, and food and beverage industries. But ... and how do pH sensors work? METTLER TOLEDO has ... in process industries with these questions and more. , ... in the process industries. The actual sensor, the pH ...
    (Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Providerâ„¢ solution ... Consummate Providerâ„¢ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
    (Date:11/18/2014)... (PRWEB) November 18, 2014 Brothers Josh ... the launch of PAWSitively Curing Cancer, Inc . ... new 501(c) (3) non-profit organization is dedicated to raising ... goes directly to the University of Florida College ... with PAWSitively Curing Cancer as the recipient of this ...
    (Date:11/18/2014)... (PRWEB) November 18, 2014 Array Architects ... and design expertise to the nation's hospitals and health ... served by those dedicating their careers to the advancement ... respected contributor in her respective field, Laura Silvoy has ... at the 2014 Winter Simulation Conference. , Laura ...
    Breaking Biology Technology:pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
    ... 2011 Syndax Pharmaceuticals, Inc. announced today ... study, demonstrated entinostat, a novel, oral small molecule inhibitor ... single agent in patients with relapsed or refractory Hodgkin,s ... 11, from 6:00 to 8:00 PM PT at the ...
    ... 2011   Life Technologies Corporation today announced that its ... annual Most Innovative New Product "MIP" Awards luncheon hosted by ... for its disruptive technology in the gene sequencing field. ... had strong uptake in research labs around the world and ...
    ... BioSpecifics Technologies Corp. (NASDAQ: BSTC ), ... marketed as XIAFLEX ® in the U.S. and ... the appointment of  George Gould, Esq., to its Board ... attorney, is Principal of George M. Gould, LLC, and ...
    Cached Biology Technology:Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 2Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4
    (Date:11/4/2014)... (Philadelphia, PA) – Temple University School of Medicine ... Explorations winner, an initiative funded by the Bill ... MPH, Professor of Obstetrics, Gynecology and Reproductive Sciences; ... at Temple University School of Medicine will pursue ... titled "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", ...
    (Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
    (Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
    Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
    ... 2013  The following is being released by Wake Forest ... What:  A briefing for ... developments at Wake Forest Baptist Medical Center. Speakers are ... John D. McConnell , ...
    ... newly described species Alburnoides manyasensis , belongs the large ... as he carps, the minnows, and their relatives. This is ... of vertebrate animals, with the remarkable numbers of over 2,400 ... the largest part of biomass in most water types except ...
    ... to Research Careers) Program has announced the travel award ... 2013 meeting in Woods Hole, MA from March 9-14, ... of underrepresented minority students, postdoctorates and scientists into the ... the participation of young scientists at The Histochemical Society ...
    Cached Biology News:Wake Forest Innovations Announces New Commercialization Developments 2